Compare OCSL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | XERS |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2007 | 2021 |
| Metric | OCSL | XERS |
|---|---|---|
| Price | $11.85 | $6.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $12.63 | $10.83 |
| AVG Volume (30 Days) | 742.0K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $0.31 | $22.86 |
| P/E Ratio | ★ N/A | $623.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $10.63 | $4.30 |
| 52 Week High | $14.77 | $10.08 |
| Indicator | OCSL | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 49.90 |
| Support Level | $11.01 | $5.81 |
| Resistance Level | $13.89 | $6.41 |
| Average True Range (ATR) | 0.24 | 0.31 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 27.21 | 30.21 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.